STERIS Announces Financial Results for Fiscal 2026 First Quarter
STERIS plc (NYSE: STE) reported strong fiscal 2026 first quarter results, with total revenue increasing 9% to $1.4 billion and constant currency organic revenue growing 8%. The company's net income from continuing operations reached $177.4 million, or $1.79 per diluted share, while adjusted EPS grew to $2.34.
Performance was driven by growth across all segments: Healthcare revenue grew 8% to $974.7 million, Applied Sterilization Technologies increased 13% to $281.2 million, and Life Sciences rose 5% to $135.2 million. Free cash flow significantly improved to $326.5 million.
STERIS updated its fiscal 2026 outlook, raising revenue growth expectations to 8-9% from 6-7%, while maintaining adjusted EPS guidance of $9.90-$10.15. The company now expects free cash flow of approximately $820 million, up from previous guidance of $770 million.
STERIS plc (NYSE: STE) ha riportato solidi risultati nel primo trimestre fiscale 2026, con un ricavo totale in aumento del 9% a 1,4 miliardi di dollari e una crescita organica a valuta costante dell'8%. L'utile netto dalle operazioni continue ha raggiunto 177,4 milioni di dollari, pari a 1,79 dollari per azione diluita, mentre l'utile per azione rettificato 猫 salito a 2,34 dollari.
La performance 猫 stata trainata dalla crescita in tutti i segmenti: i ricavi nel settore sanitario sono aumentati dell'8% a 974,7 milioni di dollari, le tecnologie di sterilizzazione applicata sono cresciute del 13% a 281,2 milioni di dollari, e le scienze della vita sono salite del 5% a 135,2 milioni di dollari. Il flusso di cassa libero 猫 migliorato significativamente, raggiungendo 326,5 milioni di dollari.
STERIS ha aggiornato le previsioni per l鈥檃nno fiscale 2026, alzando le aspettative di crescita dei ricavi all'8-9% rispetto al 6-7% precedente, mantenendo invece la guida sull'utile per azione rettificato tra 9,90 e 10,15 dollari. La societ脿 ora prevede un flusso di cassa libero di circa 820 milioni di dollari, in aumento rispetto alla precedente stima di 770 milioni.
STERIS plc (NYSE: STE) report贸 s贸lidos resultados en el primer trimestre fiscal 2026, con ingresos totales que aumentaron un 9% hasta 1.4 mil millones de d贸lares y un crecimiento org谩nico en moneda constante del 8%. El ingreso neto de operaciones continuas alcanz贸 177.4 millones de d贸lares, o 1.79 d贸lares por acci贸n diluida, mientras que las ganancias ajustadas por acci贸n crecieron a 2.34 d贸lares.
El desempe帽o fue impulsado por el crecimiento en todos los segmentos: los ingresos en salud crecieron un 8% hasta 974.7 millones de d贸lares, las tecnolog铆as de esterilizaci贸n aplicada aumentaron un 13% hasta 281.2 millones de d贸lares, y las ciencias de la vida subieron un 5% hasta 135.2 millones de d贸lares. El flujo de caja libre mejor贸 significativamente hasta 326.5 millones de d贸lares.
STERIS actualiz贸 sus previsiones para el a帽o fiscal 2026, elevando las expectativas de crecimiento de ingresos al 8-9% desde el 6-7%, mientras mantiene su gu铆a de ganancias ajustadas por acci贸n entre 9.90 y 10.15 d贸lares. La compa帽铆a ahora espera un flujo de caja libre de aproximadamente 820 millones de d贸lares, superior a la gu铆a previa de 770 millones.
STERIS plc (NYSE: STE)電� 2026 須岅硠鞐半弰 1攵勱赴 臧曤牓頃� 鞁れ爜鞚� 氤搓碃頄堨溂氅�, 齑� 毵れ稖鞚� 9% 歃濌皜頃� 14鞏� 雼煬毳� 旮半頄堦碃, 頇橃湪 氤�霃欖潉 鞝滌櫢頃� 鞙犼赴鞝� 毵れ稖鞚� 8% 靹膘灔頄堨姷雼堧嫟. 須岇偓鞚� 歆�靻� 鞓侅梾 靾滌澊鞚奠潃 1鞏� 7,740毵� 雼煬, 頋劃 欤茧嫻靾滌澊鞚奠潃 1.79雼煬鞓�鞙茧┌, 臁办爼 欤茧嫻靾滌澊鞚奠潃 2.34雼煬搿� 歃濌皜頄堨姷雼堧嫟.
氇摖 攵�氍胳棎靹� 靹膘灔靹戈皜 雮橅儉雮姷雼堧嫟: 項姢旒�鞏� 毵れ稖鞚� 8% 歃濌皜頃� 9鞏� 7,470毵� 雼煬, 鞚戩毄 氅戈窢 旮办垹 攵�氍胳潃 13% 歃濌皜頃� 2鞏� 8,120毵� 雼煬, 靸濍獏瓿柬暀 攵�氍胳潃 5% 歃濌皜頃� 1鞏� 3,520毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 鞛愳湢 順勱笀 頋愲鞚� 韥矊 臧滌劆霅橃柎 3鞏� 2,650毵� 雼煬鞐� 雼枅鞀惦媹雼�.
STERIS電� 2026 須岅硠鞐半弰 鞝勲鞚� 鞐呺嵃鞚错姼頃橂┌ 毵れ稖 靹膘灔 旮半寑旃橂ゼ 旮办〈 6-7%鞐愳劀 8-9%搿� 靸來枼 臁办爼頄堦碃, 臁办爼 欤茧嫻靾滌澊鞚� 臧�鞚措崢鞀る姅 9.90词10.15雼煬搿� 鞙犾頄堨姷雼堧嫟. 須岇偓電� 鞚挫牅 鞛愳湢 順勱笀 頋愲鞚� 鞎� 8鞏� 2,000毵� 雼煬搿� 鞓堨儊頃橂┌, 鞚挫爠 臧�鞚措崢鞀れ澑 7鞏� 7,000毵� 雼煬鞐愳劀 靸來枼 臁办爼頄堨姷雼堧嫟.
STERIS plc (NYSE: STE) a annonc茅 de solides r茅sultats pour le premier trimestre de l'exercice 2026, avec un chiffre d'affaires total en hausse de 9% 脿 1,4 milliard de dollars et une croissance organique 脿 taux de change constant de 8%. Le b茅n茅fice net des activit茅s poursuivies a atteint 177,4 millions de dollars, soit 1,79 dollar par action dilu茅e, tandis que le BPA ajust茅 est pass茅 脿 2,34 dollars.
La performance a 茅t茅 port茅e par la croissance dans tous les segments : les revenus dans le secteur de la sant茅 ont augment茅 de 8% 脿 974,7 millions de dollars, les technologies de st茅rilisation appliqu茅es ont progress茅 de 13% 脿 281,2 millions de dollars, et les sciences de la vie ont augment茅 de 5% 脿 135,2 millions de dollars. Le flux de tr茅sorerie disponible s鈥檈st nettement am茅lior茅, atteignant 326,5 millions de dollars.
STERIS a mis 脿 jour ses pr茅visions pour l鈥檈xercice 2026, augmentant ses attentes de croissance du chiffre d鈥檃ffaires 脿 8-9% contre 6-7% pr茅c茅demment, tout en maintenant ses pr茅visions de BPA ajust茅 entre 9,90 et 10,15 dollars. L鈥檈ntreprise pr茅voit d茅sormais un flux de tr茅sorerie disponible d鈥檈nviron 820 millions de dollars, en hausse par rapport 脿 la pr茅c茅dente estimation de 770 millions.
STERIS plc (NYSE: STE) meldete starke Ergebnisse f眉r das erste Quartal des Gesch盲ftsjahres 2026, mit einem Gesamtumsatzanstieg von 9% auf 1,4 Milliarden US-Dollar und einem organischen Umsatzwachstum bei konstanten Wechselkursen von 8%. Der Nettogewinn aus fortgef眉hrten Gesch盲ftsbereichen erreichte 177,4 Millionen US-Dollar, bzw. 1,79 US-Dollar je verw盲sserter Aktie, w盲hrend das bereinigte Ergebnis je Aktie auf 2,34 US-Dollar anstieg.
Das Wachstum wurde von allen Segmenten getragen: Der Umsatz im Gesundheitswesen stieg um 8% auf 974,7 Millionen US-Dollar, die Applied Sterilization Technologies wuchsen um 13% auf 281,2 Millionen US-Dollar, und die Life Sciences legten um 5% auf 135,2 Millionen US-Dollar zu. Der freie Cashflow verbesserte sich deutlich auf 326,5 Millionen US-Dollar.
STERIS aktualisierte seine Prognose f眉r das Gesch盲ftsjahr 2026 und hob die Umsatzerwartungen von 6-7% auf 8-9% an, w盲hrend die bereinigte Ergebnisprognose von 9,90 bis 10,15 US-Dollar beibehalten wurde. Das Unternehmen erwartet nun einen freien Cashflow von etwa 820 Millionen US-Dollar, gegen眉ber der bisherigen Prognose von 770 Millionen.
- Total revenue increased 9% to $1.4 billion with 8% constant currency organic growth
- Adjusted EPS grew 15% to $2.34 from $2.03 year-over-year
- Free cash flow increased significantly to $326.5 million from $195.7 million
- Revenue growth guidance raised to 8-9% from 6-7%
- Free cash flow guidance increased to $820 million from $770 million
- Increased tariff impact expected to reduce pre-tax profit by $45 million, up from $30 million previously estimated
- Higher employee healthcare benefit costs offsetting favorable foreign currency benefits
- Energy costs and labor inflation impacting operating expenses
Insights
STERIS delivered strong Q1 FY26 with 9% revenue growth, margin improvement, and raised guidance despite tariff headwinds.
STERIS has reported a robust start to fiscal 2026 with 9% total revenue growth (8% organic growth in constant currency) for Q1, reaching
Breaking down the segments, Healthcare remains the dominant revenue contributor at
The margin story is particularly encouraging, with operating income improvements across all segments despite inflationary pressures. Healthcare operating income grew to
Cash flow performance was exceptional, with free cash flow surging
The updated FY26 outlook reflects confidence, with revenue growth expectations raised to
- Total revenue from continuing operations increased
9% ; constant currency organic revenue grew8% - As reported EPS from continuing operations increased to
$1.79 ; adjusted EPS increased to$2.34 - Fiscal 2026 revenue and free cash flow outlook updated
DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (鈥淪TERIS鈥� or the 鈥淐ompany鈥�) today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased
鈥淲e are pleased with a strong start to fiscal 2026,鈥� said Dan Carestio, President and CEO of STERIS. 鈥淥ur performance exceeded expectations and margins improved nicely, despite tariff headwinds. Revenue also benefited from favorable foreign currency during the quarter, which we anticipate will continue throughout the fiscal year.鈥�
Total Company First Quarter Results from Continuing Operations
As reported, net income from continuing operations for the first quarter was
First Quarter Segment Results from Continuing Operations
Healthcare revenue as reported grew
Fiscal 2026 first quarter revenue for Applied Sterilization Technologies (AST) increased
Life Sciences first quarter revenue as reported increased
Cash Flow
Net cash provided by operations for the first quarter of fiscal 2026 was
Board Announcements
As of STERIS鈥檚 annual meeting, held July 31, 2025, the Company has announced three changes to the Board. Dr. Jaqueline Kosecoff and Dr. Richard Steeves have retired from the Board. Louis Shapiro, retired President and CEO of the Hospital for Specialty Surgery (HSS) has been elected to the Board.
鈥淲e are grateful to have benefitted from the counsel and expertise brought to the Board by Dr. Kosecoff and Dr. Steeves for many years,鈥� said Carestio. 鈥淲e wish them well in their future endeavors and thank them for their dedication to STERIS. We are excited to welcome Mr. Shapiro to our Board, as he adds additional perspective from the healthcare industry from his many years in leadership at HSS.鈥�
Fiscal 2026 Outlook Updated
For fiscal 2026, the Company now expects as reported revenue from continuing operations to increase 8
Capital expenditures are anticipated to be approximately
Conference Call
As previously announced, STERIS management will host a conference call tomorrow, August 7, 2025, at 9:00 a.m. ET. The conference call can be heard at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET tomorrow either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 2889488 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally.
About STERIS
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit www.steris.com.
Company Contact:
Julie Winter, Vice President, Investor Relations and Corporate Communications
[email protected]
Non-GAAP Financial Measures
Adjusted net income, adjusted income from operations, free cash flow, adjusted EPS and constant currency organic revenue are non-GAAP measures that may be used from time to time and should not be considered replacements for U.S. GAAP results. Non-GAAP financial measures are presented in this release with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. The Company believes that the presentation of these non-GAAP financial measures, when considered along with our U.S. GAAP financial measures, provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure.
Adjusted net income, adjusted EPS and adjusted income from operations exclude the amortization of intangible assets acquired in business combinations, acquisition and divestiture related transaction costs and gains or losses, integration costs related to acquisitions, tax restructuring costs, and certain other unusual or non-recurring items. STERIS believes this measure is useful because it excludes items that may not be indicative of or are unrelated to our core operating results and provides a baseline for analyzing trends in our underlying businesses.
The Company defines free cash flow as cash flows from operating activities less purchases of property, plant, equipment and intangibles, plus proceeds from the sale of property, plant, equipment, and intangibles. STERIS believes that free cash flow is a useful measure of the Company鈥檚 ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares.
To measure the percentage organic revenue growth, the Company removes the impact of significant acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies鈥� non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales, gross profit, operating income, net earnings and net earnings per diluted share, the most directly comparable U.S. GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company鈥檚 operations that, when viewed with U.S. GAAP results and the reconciliations to corresponding U.S. GAAP financial measures below, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded 鈥渇orward-looking statements鈥� under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆xpects,鈥� 鈥渂elieves,鈥� 鈥渁nticipates,鈥� 鈥減lans,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渢argets,鈥� 鈥渇orecasts,鈥� 鈥渙utlook,鈥� 鈥渋mpact,鈥� 鈥減otential,鈥� 鈥渃onfidence,鈥� 鈥渋mprove,鈥� 鈥渙ptimistic,鈥� 鈥渄eliver,鈥� 鈥渙rders,鈥� 鈥渂acklog,鈥� 鈥渃omfortable,鈥� 鈥渢rend,鈥� and 鈥渟eeks,鈥� or the negative of such terms or other variations on such terms or comparable terminology.
Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS鈥檚 recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS鈥檚 ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the ethylene oxide litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS鈥檚 performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS鈥檚 businesses, industry or initiatives may adversely impact STERIS鈥檚 performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS鈥檚 indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS鈥檚 Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.
Attachment
FAQ
What were STERIS (NYSE:STE) Q1 2026 earnings per share?
How much did STERIS revenue grow in Q1 2026?
What is STERIS's updated revenue guidance for fiscal 2026?
How much free cash flow did STERIS generate in Q1 2026?
What were the segment revenue results for STERIS in Q1 2026?
